Avidity Biosciences, Inc. (RNA)
NEUTRALFundamental
36
Price
$13.81
Market Cap
$226M
Part 1 · What the company is worth
Overview
Atrium Therapeutics, Inc., a biopharmaceutical company, focuses on delivering ribonucleic acid (RNA) therapeutics to the heart to transform the care for people living with cardiomyopathies. The company's development stage product candidates include ATR 1072, a siRNA-based therapy targeting PRKAG2 for the treatment of PRKAG2 syndrome; and ATR 1086, a siRNA-based therapy targeting PLN for the treatment of PLN cardiomyopathy. It also focuses on pipeline to treat a range of genetic and cardiac diseases. It has a research collaboration and license agreement with Bristol-Myers Squibb Company and Eli Lilly and Company. The company was incorporated in 2025 and is headquartered in San Diego, California.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
No editorial profile for this company yet
No competitor list for this company yet.
Balance Sheet & Liquidity
Revenue
$36M
Trailing 12 months (through 6/30/2026)
Net Income
$-448M
Trailing 12 months (through 6/30/2026)
Free Cash Flow
-
Total Equity
$1.69B
Total Liabilities
$269M
Current Ratio
8.73
Interest Coverage
-
Debt/EBITDA
-
Earnings Per Share
Revenue & Net Income
Free Cash Flow
Income Breakdown
Historical statement
Margins over time
Debt over time
How heavy the debt is
Growth grid
Growth — Revenue
Fair Value Estimation
Fair Value
$25.00
Current Price
$13.81
Margin of Safety
+44.8%
Fair Value Range
$23.75 - $26.25
Estimation Methods
Valuation Metrics
P/E Ratio
-
ROE
-40.5%
P/B Ratio
1.09
P/FCF
-
Gross Margin
-
ROIC
-153.3%
Profitability Radar
Value Creation (Economic Moat)
ROIC
-153.3%
WACC
10.2%
ROIC − WACC
-163.5 pp
ROIC is below the cost of capital — the company is destroying value for every dollar invested.
Fundamental Analysis Criteria
Passed (6)
- P/B Ratio 1.09
- Debt/Equity ratio
- Current Ratio
- Low reliance on intangibles
- Analyst Consensus 86% Buy
- Earnings Surprise avg 8.5%
Failed (9)
- EPS shows upward trend
- ROIC -153.3%
- Operating Margin -1343.1%
- Return on Tangible Assets
- DCF valuation (Unknown)
- ROE -40.3%
- Share Dilution 88.9%
- Net Margin Trend -3650.4% vs -2219.9%
- Piotroski F-Score 3/9
Unavailable (12)
- Historical price data insufficient
- Gross Margin NaN%
- P/FCF NaN
- Dividend Payout NaN%
- Positive Free Cash Flow
- CapEx intensity
- Interest Coverage
- Debt/EBITDA
- Price below Graham Number
- Revenue Growth 5Y (Finnhub)
- PEG Ratio (need PE > 0 and growth > 0)
- Earnings Quality (OCF/Net Income)
Piotroski F-Score
Serious financial concerns
Earnings Quality
Low quality: investigate accounting
Share Dilution
Issuing new shares, diluting ownership
Governance
Executive Team
| Name | Title | Age |
|---|---|---|
| Ms. Kathleen P. Gallagher | President, CEO & Director | 44 |
| Mr. Brendan Winslow | Chief Financial Officer | 37 |
| Dr. Husam Younis Ph.D., Pharm.D. | Chief Scientific Officer | 51 |
| Ms. Stephanie Kenney | Chief Corporate Affairs Officer | 47 |
| Dr. Steven George Hughes M.B.A., M.D. | Chief Medical Officer | 58 |
| Ms. Rocio Martin Hoyos | Chief Strategy Officer | 42 |
Part 2 · The price and when to enter
This part won't tell you whether the company is worth owning: it helps you choose when to buy it, once the fundamentals have convinced you. Inside: technical analysis, potential, historical drawdowns, gamma exposure.
Latest News
Recent headlines for RNA, sourced from Markets Gazette.